Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong

About this trial

(a) Objectives

1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • third dose vaccination with CoronaVac vaccine
  • third dose vaccination with BionTech vaccine
  • Vaccination with Coronavac vaccine
  • Vaccination with BionTech Vaccine

Treatment groups

700 Participants
are divided into 5 treatment groups

Sponsors and collaborators

Chinese University of Hong Kong

Lead sponsor

The University of Hong Kong

Collaborator

Health and Medical Research Fund

Collaborator